Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SODIUM ZIRCONIUM CYCLOSILICATE vs SPS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sodium zirconium cyclosilicate is a non-absorbed, inorganic, potassium-selective cation exchanger that binds potassium ions in the gastrointestinal tract, thereby reducing the absorption of potassium and facilitating its fecal excretion. It exchanges sodium and hydrogen for potassium in the gut lumen.
SPS (sodium polystyrene sulfonate) is a cation-exchange resin that exchanges sodium ions for potassium ions in the gastrointestinal tract, primarily in the colon, thereby reducing serum potassium levels.
FDA-approved: Treatment of hyperkalemia in adults.,Off-label: Chronic hyperkalemia management in patients on renin-angiotensin-aldosterone system inhibitors; acute hyperkalemia in emergency settings (limited data).
Treatment of hyperkalemia
5 g orally three times daily.
15-60 g orally 1-4 times daily; administer as a suspension in water or juice. Alternatively, 30-50 g rectally as a retention enema every 6 hours.
Not applicable as the drug acts locally in the GI tract without systemic absorption; clinical effect persists for duration of dosing.
Not applicable; SPS acts locally in the gastrointestinal tract and does not undergo systemic absorption. No terminal half-life can be defined.
Sodium zirconium cyclosilicate is not systemically absorbed and is eliminated unchanged in feces. No hepatic metabolism or cytochrome P450 involvement.
SPS is not absorbed systemically and is excreted unchanged in the feces.
Primarily eliminated unchanged in feces (>99%); negligible renal excretion (<1%) as the drug is not absorbed systemically.
SPS (sodium polystyrene sulfonate) is a cation-exchange resin that is not absorbed systemically. It is excreted entirely in the feces, with no renal or biliary elimination. The resin-bound potassium is eliminated via the gastrointestinal tract.
Not applicable; <0.1% absorbed systemically, so protein binding is negligible.
Not applicable; SPS is not absorbed and does not bind to plasma proteins.
Not applicable; negligible systemic distribution due to lack of absorption (Vd not measurable).
Not applicable; SPS remains within the gastrointestinal lumen and does not distribute into body tissues. Reported Vd is negligible.
Oral: <0.1% due to minimal absorption; acts locally in gastrointestinal tract.
Oral: 0% (not absorbed); rectal: 0% (not absorbed). SPS acts locally without systemic availability.
No dose adjustment required for any degree of renal impairment.
No specific dose adjustment is recommended based on GFR. Use with caution in patients with renal impairment due to risk of electrolyte disturbances (e.g., hypernatremia, hypokalemia).
No dose adjustment required for any degree of hepatic impairment.
No dose adjustment required for hepatic impairment. Monitor serum electrolytes and fluid balance in patients with hepatic disease.
Safety and efficacy not established in pediatric patients.
Children (2-12 years): 0.5-2 g/kg/day divided every 4-6 hours; maximum 30 g/day. Administer orally or rectally as per adult guidance.
No specific dose adjustment recommended; use with caution due to potential for electrolyte disturbances.
Use lowest effective dose; monitor electrolyte levels and renal function more frequently due to age-related decline in renal function and increased risk of electrolyte imbalance.
None
No FDA black box warning.
Edema: Contains sodium; caution in patients with heart failure or requiring sodium restriction (each 5 g dose provides ~400 mg sodium).,Gastrointestinal effects: Constipation, fecal impaction (especially in elderly or those with decreased GI motility).,Hypokalemia: Monitor serum potassium regularly; may cause hypokalemia if not titrated appropriately.,Drug interactions: Separate dosing from oral medications (take at least 2 hours apart) due to potential adsorption.,Severe constipation: Discontinue if bowel obstruction suspected.
Risk of intestinal necrosis, particularly with concomitant use of sorbitol,Electrolyte disturbances (e.g., hypokalemia, hypocalcemia, hypernatremia),Use with caution in patients with gastrointestinal disorders or postoperative patients
Absolute: Hypersensitivity to sodium zirconium cyclosilicate or any component.,Relative: Severe constipation, bowel obstruction, or impaired GI motility (e.g., postoperative ileus) – use only if benefits outweigh risks.,Relative: Concomitant use with agents that cause constipation or reduce GI motility.
Hypokalemia,Obstructive bowel disease,Neonates with reduced gut motility (postoperative or drug-induced),Concurrent use with sorbitol
No specific food restrictions. However, patients should continue to follow dietary potassium restrictions as advised by their healthcare provider. SZC works in the gastrointestinal tract and does not interfere with food absorption. Avoid taking with high-fat meals as it may delay the onset of action.
Avoid high-potassium foods such as bananas, oranges, tomatoes, potatoes, and spinach to prevent excessive potassium intake. SPS may bind to some foods, but no specific food restrictions beyond potassium-rich foods are required. Do not mix SPS with fruit juices; use only water or simple syrup.
Limited human data; animal studies show no teratogenic effects at clinically relevant exposures. Not associated with structural abnormalities in first trimester. Theoretical risk of electrolyte disturbances affecting fetal development if maternal electrolyte imbalance occurs. No known risk in second or third trimester.
SPS (sodium polystyrene sulfonate) is not absorbed systemically; therefore, no direct fetal risk is expected. However, electrolyte disturbances (e.g., hypokalemia, hypocalcemia) from maternal use could indirectly affect the fetus. First trimester: No known teratogenic effects. Second/Third trimester: Risk of maternal electrolyte imbalance may impact fetal development. Use only if clearly needed.
No data on excretion in human milk. Sodium zirconium cyclosilicate is non-systemic and minimally absorbed (<1% oral dose), unlikely to enter breast milk. M/P ratio not calculated due to negligible systemic absorption.
Excretion into breast milk is unlikely due to non-absorbable nature. M/P ratio not applicable. Considered compatible with breastfeeding, but monitor infant for electrolyte disturbances if maternal use is prolonged.
No dose adjustment required based on pharmacokinetic changes in pregnancy; sodium zirconium cyclosilicate acts locally in gastrointestinal tract and is not absorbed. Standard dosing: 5 g or 10 g three times daily for hyperkalemia, not to exceed 15 g per day.
No pharmacokinetic changes expected due to lack of absorption. Standard dosing may be used, but monitor electrolytes frequently due to altered renal function and volume of distribution in pregnancy. Dose adjustments are not required, but lower doses may suffice to avoid severe electrolyte shifts.
Sodium zirconium cyclosilicate (SZC) is a non-absorbed potassium binder for chronic hyperkalemia. Onset of action is 1 hour; typically used for maintenance after acute correction. Do not use as emergency treatment for life-threatening hyperkalemia (prefer IV calcium, insulin+glucose). Administer at least 2 hours apart from other oral medications due to potential binding. Monitor serum potassium regularly; adjust dose based on potassium levels. Avoid in patients with severe constipation, bowel obstruction, or impaction.
SPS (sodium polystyrene sulfonate) is a potassium-lowering resin that exchanges sodium for potassium in the GI tract. Administer orally or as a retention enema. Monitor for hypokalemia, hypomagnesemia, and sodium overload. Contraindicated in patients with bowel obstruction, severe constipation, or postoperative ileus due to risk of intestinal necrosis. Use with caution in patients on NSAIDs or with risk of colonic necrosis. Do not mix with sorbitol; use of sorbitol increases risk of intestinal necrosis. Monitor serum potassium levels frequently.
Take this medication exactly as prescribed, usually three times a day with meals for the first 24-72 hours, then once daily.,Do not crush or chew the powder; mix the packet with about 3 tablespoons (45 m L) of water and drink immediately.,Separate this medication from other oral medicines by at least 2 hours to avoid affecting their absorption.,You may experience constipation or swelling (edema); report severe constipation or swelling to your healthcare provider.,Do not use as a rescue treatment for sudden high potassium; seek emergency care if you have chest pain, irregular heartbeat, or muscle weakness.
Take this medication exactly as prescribed, usually 1 to 4 times a day.,Do not mix SPS with orange juice or other fruit juices; it should be mixed with water or syrup.,This medication may cause constipation, so drink plenty of fluids and eat high-fiber foods.,If you experience severe constipation, severe abdominal pain, vomiting, or blood in vomit or stool, seek medical attention immediately.,Avoid taking other medications within 3 hours of SPS as it may bind to them and reduce their effectiveness.,Inform your doctor if you have a history of bowel obstruction, constipation, or kidney disease.,Do not use sorbitol or other laxatives with SPS unless directed by your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SODIUM ZIRCONIUM CYCLOSILICATE vs SPS, answered by our medical review team.
SODIUM ZIRCONIUM CYCLOSILICATE is a Potassium Binder that works by Sodium zirconium cyclosilicate is a non-absorbed, inorganic, potassium-selective cation exchanger that binds potassium ions in the gastrointestinal tract, thereby reducing the absorption of potassium and facilitating its fecal excretion. It exchanges sodium and hydrogen for potassium in the gut lumen.. SPS is a Potassium Binder that works by SPS (sodium polystyrene sulfonate) is a cation-exchange resin that exchanges sodium ions for potassium ions in the gastrointestinal tract, primarily in the colon, thereby reducing serum potassium levels.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SODIUM ZIRCONIUM CYCLOSILICATE and SPS depend on the specific clinical indication. These are both Potassium Binder agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SODIUM ZIRCONIUM CYCLOSILICATE is: 5 g orally three times daily.. The standard adult dose of SPS is: 15-60 g orally 1-4 times daily; administer as a suspension in water or juice. Alternatively, 30-50 g rectally as a retention enema every 6 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SODIUM ZIRCONIUM CYCLOSILICATE and SPS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SODIUM ZIRCONIUM CYCLOSILICATE is classified as Category C. Limited human data; animal studies show no teratogenic effects at clinically relevant exposures. Not associated with structural abnormalities in first trimester. Theoretical risk o. SPS is classified as Category C. SPS (sodium polystyrene sulfonate) is not absorbed systemically; therefore, no direct fetal risk is expected. However, electrolyte disturbances (e.g., hypokalemia, hypocalcemia) fr. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.